Patents by Inventor Austin L. Gurney

Austin L. Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20230279101
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 7, 2023
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 11512128
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 29, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20220340653
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: October 27, 2022
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR, Austin L. Gurney, Ming-Hong Xie
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220213184
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: July 7, 2022
    Inventors: David P. Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220213183
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: July 7, 2022
    Inventors: David P Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220204606
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: June 30, 2022
    Inventors: David P Arnott, Mercedesz Balazs, Nico Ghilardi, Austin L. Gurney, Philip E. Hass, Sarah Hymowitz, James M. Lee, Wenjun Ouyang, Melissa A. Starovasnik, Yan Wu
  • COMBINATION THERAPY FOR TREATMENT OF DISEASE
    Publication number: 20210403553
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 26, 2021
    Publication date: December 30, 2021
    Inventors: Christopher Lamond Murriel, Timothy Charles Hoey, Austin L. Gurney, Julie Michelle Roda, Minu K. Srivastava, Inkyung Park, Jakob Dupont
  • Combination therapy for treatment of disease
    Patent number: 11046760
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: June 29, 2021
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Christopher Lamond Murriel, Timothy Charles Hoey, Austin L. Gurney, Julie Michelle Roda, Minu K. Srivastava, Inkyung Park, Jakob Dupont
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20210061903
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 4, 2021
    Inventors: AUSTIN L. GURNEY, Aaron Ken Sato, Christopher John Bond
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200385452
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: December 2, 2019
    Publication date: December 10, 2020
    Applicant: Genentech, Inc.
    Inventors: David P. ARNOTT, Austin L. GURNEY, Philip E. HASS, James M. LEE, Yan WU
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200377585
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: February 6, 2020
    Publication date: December 3, 2020
    Applicant: Genentech, Inc.
    Inventors: David P. ARNOTT, Mercedesz BALAZS, Nico GHILARDI, Austin L. GURNEY, Philip E. HASS, Sarah HYMOWITZ, James M. LEE, Wenjun OUYANG, Melissa A. STAROVASNIK, Yan WU
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200377584
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: January 7, 2020
    Publication date: December 3, 2020
    Inventors: David P. ARNOTT, Austin L. GURNEY, Philip E. HASS, James M. LEE, Yan WU
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 10730940
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 4, 2020
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • TIGIT-binding agents and uses thereof
    Patent number: 10544219
    Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: January 28, 2020
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Ming-Hong Xie
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20190100583
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: April 27, 2018
    Publication date: April 4, 2019
    Inventors: David P. ARNOTT, Austin L. GURNEY, Philip E. HASS, James M. LEE, Yan WU
  • INHIBITION OF IL-17 PRODUCTION
    Publication number: 20190092829
    Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.
    Type: Application
    Filed: April 19, 2018
    Publication date: March 28, 2019
    Applicant: Genentech, Inc.
    Inventor: Austin L. GURNEY
  • Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides
    Patent number: 10232017
    Abstract: Polypeptides and agents that bind a TNF receptor superfamily protein are disclosed, particularly agents that specifically bind GITR, OX40, or CD40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising GITRL, OX40L, or CD40L and/or bispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 19, 2019
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventor: Austin L Gurney
  • TIGIT-BINDING AGENTS AND USES THEREOF
    Publication number: 20190077864
    Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 14, 2019
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: AUSTIN L. GURNEY, Ming-Hong Xie
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20190062424
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: August 29, 2018
    Publication date: February 28, 2019
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • REDIRECTING IMMUNE RESPONSES
    Publication number: 20190048094
    Abstract: Agents that specifically bind tumor-associated antigens (TAA) and comprise an exogenous polypeptide or peptide that can be presented by a tumor cell are disclosed. The TAA-binding agents may include antibodies and/or bispecific agents. Also disclosed are methods of using the agents for redirecting an existing immune response against tumor cells and/or treatment of diseases such as cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 14, 2019
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Cecile CHARTIER-COURTAUD